definiens: Competing : Entity " means any comoration or·other entity or person whose business activities prior to the·trarisaction mclli - de : the development promotion, sale, resale, -distribution or other cOIDinercl'alizatioi1 of my Viscosupplenient':Product in the Territory, and either ( n whose sales or otherreverines : rehlted to s'uchproduci constitUted more than twenty percent ( 20 % ) of the aggtegate, reverines'oftheentity duriilg the four ( 4.}:-fUll fiscal quarters immediately preceding the ' earlier ' of conSumnianOl1.:of or public announcement of entering into an agreement with respect to any such transaction, or(ii ) whose expenses or - other expenditures related to the development of sucbproduct constituted more than twenty percent ( 20 % ) of the aggregate research and development expenses·ofthe 12 CONFIDENTIAL TREATMENT REQUESTED entity dlllihlg thefour·t41 : fun ~ fiscat .quarters iniinediately precediDg, the.:earlier .of, coiiSUmtiiation of entering into : anagreemeIit with respect to . ' any such transaction : ( d ): . ' ; ', Linutation, on Remedies ., In the .eventthatWyeth.:fal1S;to.:compl¥·~Mth t1te;covenarit set ~ forth ; in~8ecti~~:'5 ~ l(a),:at;allY ' titliec : afierthe ' ' fifth,;annivetsag'~dtilieiGi()siil~'})ate ; GeDz¥me'ssole;,rem ~ ay-;artsihg : from, srich:.non - compliance sha.n':be':theii@if1o)~~iaie n1 ~ g contingent pavnients : to : Wyeth:~Uttder Section 7~40fthisAgreement 5.2 Synvisc Adverse Medical Experiences Obligations . [COMPANY] shall remain responsible for all adverse event follow up, appropriate due diligence, and timely forwarding of adverse event related information to Genzyme Pharmacovigilance in accordance with the Pharmacovigilance Procedures Addendum effective October 29,2003 for all adverse experiences ( including adverse events associated with literature review ) received prior to the Closing Date